The purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.

This is a multicenter, open-label, two-group dose-escalation, phase I/II study in 10 severe heart failure patients (five in the low-dose group and five in the high-dose group) with underlying ischemic heart disease.

After screening period is completed, subjects undergo HS-001 CS transplantation. After transplantation, subjects take immunosuppressant and have efficacy/safety assessments.

Inclusion Criteria:

• Patients with resting left ventricular ejection fraction (LVEF) ≦40% based on institutional assessment on either screening cardiac MRI or echocardiographic assessment
• New York Heart Association (NYHA) cardiac function classification of grade II or higher at screening
• Other Criteria apply, please contact the investigator

Exclusion Criteria:

• Patients screened less than 1 month after the onset of myocardial infarction
• Patients with congenital heart disease, or cardiac sarcoidosis
• Other Criteria apply, please contact the investigator